Wen Jiang, MD, PhD
Department of CNS - Rad Onc Clinical, Division of Radiation Oncology
About Dr. Wen Jiang
Dr. Jiang is currently an Associate Professor with tenure in the Department of Radiation Oncology and a Physician-Scientist in the CNS section. Dr. Jiang received his PhD in Bioengineering from the University of Toronto and his MD from Stanford University. He completed his residency training at MD Anderson Cancer Center in 2018. He subsequently joined UT Southwestern Medical Center as a tenure-track assistant professor of Radiation Oncology and a CPRIT Scholar prior to returning to MD Anderson in 2021. Dr. Jiang cares for patients with primary and secondary CNS tumors. His research focuses on the understanding of immune suppressive mechanisms within solid tumors and identifying novel therapeutic strategies to overcome immune escape. Dr. Jiang’s research is supported by CPRIT, NCI, NINDS, the Department of Defense, the American Cancer Society, and the Susan G. Komen Foundation.
Present Title & Affiliation
Primary Appointment
Associate Professor, CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | Stanford University, Stanford, California, US, MD |
| 2008 | University of Toronto, Toronto, CA, Biomedical Engineering, Ph.D |
| 2003 | Carleton University, Ottawa, CA, Electrical Engineering, BS |
Postgraduate Training
| 2014-2018 | Clinical Residency, Radiation Oncology, MD Anderson Cancer Center, Houston, Texas |
| 2013-2014 | Clinical Internship, Internal Medicine, Santa Clara Valley Medical Center, San Jose, California |
| 2009-2013 | Research Fellowship, Tumor Immunology, Stanford School of Medicine, Stanford, California |
| 2008-2009 | Research Fellowship, Tumor Biology, Massachusetts General Hospital, Boston, Massachusetts |
Licenses & Certifications
| 2020 | DEA |
| 2019 | American Board of Radiology |
| 2018 | Texas Medical License |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Assistant Professor, Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, 2018 - 2021
Other Professional Positions
Founding co-Director, UT MD Anderson, Houston, Texas, 2026 - Present
Adjunct Professor, Bioengineering, Rice University, Houston, Texas, 2026 - Present
Intramural Institutional Committee Activities
Member, Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Odyssey Fellowship Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Extramural Institutional Committee Activities
Co-lead, Clinical Immunology Working Group, The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, Immunotherapy Platform Executive Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Physician Scientist Faculty Recruitment Panel, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Breakthrough Cancer GBM Team, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Brain Tumor Center Executive Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Radiation Oncology Strategic Initiative (ROSI) ImmunoRT Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Honors & Awards
| 2026 - Present | Elected Fellow, American Institute for Medical and Biological Engineering (AIMBE) |
| 2025 - Present | Elected Member, American Society for Clinical Investigation |
| 2024 | Andrew Sabin Family Foundation Fellowship, UT-MD Anderson Cancer Center |
| 2024 | Willie Tichenor Fellowship in Sarcoma Research, UT-MD Anderson Cancer Center |
| 2023 | Faculty Scholar Award, UT MD Anderson Cancer Center |
| 2023 | Faculty Research Excellence Award, UT MD Anderson Cancer Center |
| 2019 | NCI K08 Mentored Clinician-Scientist Career Development Award, NCI |
| 2019 | Circle of Friends Cancer Research Award, UT Southwestern |
| 2018 | A. Lavoy Moore Endowed Clinical Fellow, MD Anderson |
| 2018 | Jeffrey Lee Cousins Fellowship in Lung Cancer Research, MD Anderson |
| 2018 | Rising STARS Award, University of Texas System |
| 2018 | CPRIT Scholar in Cancer Research, CPRIT |
| 2017 | ASCO Young Investigator Award, Conquer Cancer Foundation |
| 2017 | Susan Papizan Dolan Fellowship in Breast Oncology, MD Anderson |
| 2017 | Annual Meeting Travel Award, ASTRO |
| 2017 | Roentgen Resident/Fellow Research Award, RSNA |
| 2016 | Travel Award, RSNA Annual Meeting |
| 2016 | Trainee Award - E.D. Montague Research Excellence Award, MD Anderson |
| 2016 | Workshop on Methods in Clinical Cancer Research, AACR/ASCO - Vail, CO |
| 2016 | Research Resident Grant, RSNA Annual Meeting |
| 2015 | Trainee Award – Gilbert Fletcher Society Award, MD Anderson |
| 2014 | Young Alumni Achievement Award, Carleton University |
| 2011 | Banting Postdoctoral Fellowship Award, Government of Canada |
| 2010 | Scholar Research Fellowship, Stanford Medical |
| 2008 | 1st Place: School of Graduate Studies, University of Toronto |
| 2008 | Post-Doctoral Fellowship, Natural Science and Engineering Research Council of Canada |
| 2008 | John Leyerle-Canadian Institute for Advanced Research (CIFAR) Award, Canadian Institute for Advanced Research (CIFAR) |
| 2008 | Distinguished Graduate Student Dissertation Award, University of Toronto |
| 2008 | Brain Star National Award, Canadian Institutes of Health Research (CIHR) |
| 2008 | Graduate Student Award, National Cancer Institute of Canada (NCIC) |
| 2008 | Paul B. Madsen Award, University of Toronto |
| 2005 | Alexander Graham Bell Canada Scholarship for Doctoral Studies, NSERC |
| 2003 | Senate Medal for Outstanding Academic Achievement, Carleton University |
| 2003 | Ontario Graduate Scholarship for Academic Excellence, Ontario |
| 2002 | Chipworks Award for Excellence in Electrical Engineering, Carleton University |
| 1999 - 2003 | Dean’s Honor List, Carleton University |
| 1999 | Nortel Networks Scholarship, Nortel Networks |
| 1999 | Ottawa Hydro Top Electrical Engineer Scholarship, Ottawa |
| 1999 | Ontario Scholar, Ontario |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. mRNA Delivery Platform. Invited. Investigational Cancer Therapeutics Horizons Meeting. Houston, Texas, US.
- 2024. Nucleic acids as a new target for treating cancer and other human diseases. Invited. Department of Genetics Research Exchange Seminar Series. Houston, Texas, US.
- 2023. The Quest for the Next Cancer Therapy Pillar that Complements RT. Invited. Radiation Oncology Grant Rounds. Houston, Texas, US.
- 2023. Messenger Reloaded: mRNA Therapy for Cancer and Other Human Disease. Invited. Leading Edge of Cancer Research Symposium. Houston, Texas, US.
- 2023. Bioengineering strategies to cancer immunotherapy. Invited. James P. Allison Institute Seminar Series. Houston, Texas, US.
- 2023. Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Invited. Research Town Hall, US.
- 2022. Targeting Innate Immune Checkpoints for Cancer Therapy. Invited. Cancer Biology Seminar Serie. Houston, Texas, US.
- 2022. Engineering approaches to cancer therapy. Invited. Brain Tumor Program Seminar Series. Houston, Texas, US.
- 2020. Phagocytosis Checkpoints as New Target for Cancer Immunotherapy. Invited. Young Faculty Seminar. Dallas, TX, US.
Regional Presentations
- 2023. Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Conference. MD Anderson Cancer Center, US.
- 2020. Phagocytosis Checkpoints as New Target for Cancer Immunotherapy. Conference. UTSW Medical Center. Dallas, TX, US.
National Presentations
- 2025. Engineering approaches to cancer immunotherapy. Invited. Radical Seminar Series. Stanford, CA, US.
- 2024. Engineering in vivo chimeric antigen receptor macrophages (CARMs) using mRNA-exosomes for cancer immunotherapy. Invited. 2024 NCI Alliance for Nanotechnology in Cancer Principal Investigator Meeting. Rockville, MD, US.
- 2023. Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Conference. MD Anderson Research Townhall. Houston, US.
- 2023. Engineering approaches to cancer Therapy., Cancer Biology Seminar Series. Conference. Department of Cancer Biology. Houston, US.
- 2021. Targeting Phagocytosis for GBM Immunotherapy. Invited. American Brain Tumor Association, US.
- 2020. Improving immune-vascular crosstalk for cancer immunotherapy,. Invited. AACR Annual Meeting, Virtual, US.
- 2017. Selective macrophage evading nanomedicine enables enhanced delivery and therapeutic efficacy of anti-cancer agents against solid tumors. Invited. Gordon Research Conference. Mount Snow, VT, US.
- 2017. Chemoradiation Combined with Phosphatidylserine-Targeting Antibody Enhances Systemic Antitumor immune Responses. Conference. ASTRO Annual Meeting. San Diego, CA, US.
- 2016. Circulating Lymphocyte Count During Neoadjuvant Chemoradiation Therapy for Esophageal Cancer as a Predictive Biomarker of Pathologic Complete Response. Conference. ASTRO Annual Meeting. Boston, MA, US.
- 2016. CD4:CD8 Ratio in Mycosis Fungoides: Prognostic and Predictive Value of Circulating T lymphocyte Subsets for Outcomes after Total Skin Electron Beam Radiation. Conference. ASTRO Annual Meeting. Boston, MA, US.
- 2015. Circulating myeloid precursor profile as potential marker to differentiate radiation changes from tumor recurrence after brain stereotactic radiosurgery. Conference. AACR Annual Meeting. Philadelphia, PA, US.
- 2015. Temporally-Dependent Intracranial Control of Melanoma Brain Metastasis by Stereotactic Radiation Therapy in Patients Treated With Immune Checkpoint Blockade. Conference. ASTRO Annual Meeting. San Antonio, TX, US.
- 2015. Microenvironmental modulation improves nanomedicine delivery into brain tumors. Conference. SNO Annual Scientific Meeting. San Antonio, TX, US.
International Presentations
- 2025. Skeletal muscle–targeted non-viral delivery of full-length dystrophin mRNA for Duchenne muscular dystrophy. Conference. CRS Singapore 2025. Singapore, SG.
- 2024. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Conference. Controlled Release Society Annual Meeting & Expo. Bologna, IT.
- 2023. Cancer Immunotherapy based on Image-Guided STING Activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Invited. International Soceity for Therapeutic Ultrasound (ISTU), US.
- 2022. Microbubble-assisted Ultrasound Sound-guided Immunotherapy of Cancer (MUSIC). Invited. Controlled Release Society (CRS) Annual Meeting. Montreal, CA.
- 2015. Temporally dependent intracranial control of melanoma brain metastasis by stereotactic radiotherapy in patients treated with immune-checkpoint blockade. Conference. Gilbert H. Fletcher Society Annual Meeting. Hunan, CN.
Formal Peers
- 2022. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Invited, US.
- 2021. Targeting Innate Immune System for Cancer Therapy. Invited. Houston, TX, US.
- 2020. Phagocytosis checkpoints as new cancer immunotherapy. Invited, US.
- 2018. Therapeutic targeting of tumor microenvironment for cancer immunotherapy. Invited, US.
- 2018. Tumor microenvironment as new target for cancer therapy. Invited, US.
- 2018. Targeting the tumor microenvironment for cancer therapy,. Invited, US.
- 2018. Targeting the tumor microenvironment for cancer immunotherapy. Invited, US.
- 2017. Tumor microenvironment as a new target for cancer therapy. Invited, US.
- 2017. Targeting the tumor microenvironment for cancer therapy. Invited, US.
Grant & Contract Support
| Date: | 2026 - 2026 |
| Title: | ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant |
| Funding Source: | American Society for Radiation Oncology (ASTRO) |
| Role: | Mentor |
| Date: | 2026 - 2031 |
| Title: | Cancer Engineering Program |
| Funding Source: | UT MD Anderson |
| Role: | Co-PI |
| Date: | 2026 - 2028 |
| Title: | Engineering next-generation mRNA therapy for oligodendroglioma |
| Funding Source: | Oligo Nation |
| Role: | Co-PI |
| ID: | FP00029736 |
| Date: | 2026 - 2028 |
| Title: | Ultrasound-guided cancer immunotherapy with targeted nanodroplets |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | R21CA304638 |
| Date: | 2026 - 2031 |
| Title: | Ultrasound-Guided Neoadjuvant Delivery Platform to Enhance Immunotherapy for Metastatic Melanoma |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2026 - 2031 |
| Title: | Engineering a Bispecific HER2-CD47 Antibody Toxin Conjugate (ATC) for Cancer Immunotherapy |
| Funding Source: | NCI |
| Role: | PI |
| ID: | 1R01CA319201-01 |
| Date: | 2025 - 2028 |
| Title: | Ultrasound-Guided Adjuvant Activation of Innate Immunity in Metastatic Breast Cancer |
| Funding Source: | DoD |
| Role: | Co-I |
| ID: | BC250342 |
| Date: | 2025 - 2029 |
| Title: | Targeting the Untargetable: Novel Therapy for SMARCB1-deficient Pediatric and Adolescent Cancers |
| Funding Source: | Cancer Prevention Research Inst. of TX |
| Role: | PI |
| Date: | 2025 - 2028 |
| Title: | Ultrasound-Guided Neoadjuvant Activation of Innate Immunity in Metastatic Melanoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP260192 |
| Date: | 2025 - 2030 |
| Title: | Microbial-inspired immune-stimulating antibody-toxin conjugate for cancer immunotherapy |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | 1R01CA305986-01 |
| Date: | 2025 - 2028 |
| Title: | Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP230307 |
| Date: | 2024 - 2026 |
| Title: | Engineering in vivo chimeric antigen receptor macrophages for diffuse midline glioma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240493 |
| Date: | 2024 - 2026 |
| Title: | Engineering a Targeted, Acoustically Responsive Image-Guided GBM Immunotherapy |
| Funding Source: | American Brain Tumor Association |
| Role: | PI |
| ID: | ARC2400008 |
| Date: | 2024 - 2029 |
| Title: | Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA291876 |
| Date: | 2024 - 2028 |
| Title: | Ultrasound-mediated activation of STING using a clinical scanner for the immunotherapy of cancer |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | RSG23-1155943-01 |
| Date: | 2023 - 2027 |
| Title: | Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | 1R01CA284108-01 |
| Date: | 2022 - 2024 |
| Title: | Reversing Aging Associated Resistance to Cancer Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP220553 |
| Date: | 2022 - 2026 |
| Title: | Glioblastoma immunotherapy with dual phagocytosis checkpoint blockade |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | 2021ACS000RSG0000218113 |
| Date: | 2022 - 2025 |
| Title: | A Novel Selective IL-2 Mimic for Combination Immunotherapy of Breast Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP220357 |
| Date: | 2022 - 2023 |
| Title: | Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21 CA252344 |
| Date: | 2022 - 2022 |
| Title: | Eliciting abscopal effect of combined radiotherapy, PD-1 blockade and NL-201 in localized and metastatic cancers |
| Funding Source: | Neoleukin Inc |
| Role: | PI |
| ID: | LS2022-00060546-JW |
| Date: | 2021 - 2022 |
| Title: | Engaging the Immune System to Improve Metastatic Breast Cancer Treatment |
| Funding Source: | Susan G. Komen Foundation |
| Role: | PI |
| ID: | CCR19605871 |
| Date: | 2021 - 2026 |
| Title: | 6-thio-deoxyguanosine: A Novel Immunogenic Telomerase-mediated Therapy in Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U19CA264385 |
| Date: | 2021 - 2024 |
| Title: | Treating Metastatic Cancer using Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (MUSIC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP210199 |
| Date: | 2021 - 2023 |
| Title: | Circulating Exosome-Based Biomarker for Treatment Monitoring in Anal Cancer |
| Funding Source: | Radiation Oncology Institute |
| Role: | PI |
| ID: | ROI2021-9131 |
| Date: | 2021 - 2025 |
| Title: | Ultrasound-Guided Targeted STING Activation for Breast Cancer Immunotherapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH21-1-0332 |
| Date: | 2021 - 2026 |
| Title: | Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | R01NS117828 |
| Date: | 2021 - 2023 |
| Title: | A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5K08CA241070-02 |
| Date: | 2019 - 2021 |
| Title: | Bridging Innate and Adaptive Glioblastoma Immunity via Phagocytosis Checkpoint Blockade |
| Funding Source: | American Brain Tumor Association |
| Role: | PI |
| ID: | DG1900021 |
| Date: | 2019 - 2021 |
| Title: | CD24 as a novel therapeutic target for glioblastoma immunotherapy |
| Funding Source: | UT Southwestern Simmons Cancer Center |
| Role: | PI |
| Date: | 2018 - 2023 |
| Title: | First time, tenure track faculty recruitment award |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR180017 |
| Date: | 2018 - 2019 |
| Title: | UT Rising Stars Award |
| Funding Source: | University of Texas Systems |
| Role: | PI |
| Date: | 2017 - 2018 |
| Title: | High throughput multiplexed immunological profiling of glioblastoma |
| Funding Source: | ASCO/Conquer Cancer Foundation |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Combining chemoradiation with anti-phosphatidylserine blockade promotes immunogenic phagocytosis to generate long-lasting anti-tumor immunity |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Ha, JH, Wang, Y, Ma, Y, Wu, A, Dong, S, Jeong, S, Edwards, J, Chang, M, Chang, YT, Wang, X, Dufilho, M, Najarro Torres, M, McCabe, S, Deng, W, Grippin, A, Weinberg, J, Raza, SM, DeMonte, F, McCutcheon, IE, Prabhu, SS, Ferguson, SD, Ene, CI, Akdemir, KC, Basu, S, Jindal, S, Schrank, B, Hu, J, Goswami, S, Puduvalli, VK, Lang Jr, FF, Huntoon, K, Sharma, P, Kim, BY, Jiang, W. Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. Nature communications 17(1), 2026. e-Pub 2026. PMID: 41803138.
- Chang M, Wang Y, Ha J, Neale ZR, Ajami NJ, Diggs LP, Nalin AP, Ma Y, Dong S, Hoballah YM, Day A, Jeong SD, Wu A, Schrank BR, Edwards JL, Wang T, Wang X, Chang YT, Tang C, Lim AJ, Torres MN, Deng W, Peitsch T, Dufilho MJ 4th, Goswami S, Jiang D, Koong AC, Sharma P, Wargo JA, Jiang W, Kim BYS. A transferable gut microbiota-bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response. Nat Mater 25(9):1634-1645, 2026. e-Pub 2026. PMID: 42538384.
- Carriere, P, Haisraely, O, Aaroe, AE, Ahmed, K, Lewis, R, Colson-Fearon, D, Bolden, M, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, McAleer, MF, Ghia, AJ, Jiang, W, Chung, C, Grosshans, DR, Ballester, L, Esquenazi, Y, Kamiya Matsuoka, C, Yeboa, DN. Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology. Journal of neuro-oncology 179(1), 2026. e-Pub 2026. PMID: 42489814.
- Wu A, Jeong SD, Schrank BR, Kim BYS, Sharma P, Jiang W. Programming the immunological properties of mRNA vaccines for cancer. Nature Rev Immunol, 2026. e-Pub 2026. PMID: 42321479.
- Tian Y, Liu Y, Tong Y, Huntoon K, Yang L, Shi J, Ma Y, Dong S, Jeong SD, Estania AP, Yi Y, Kwak KJ, Wang Y, Wu A, Edwards JL, Wang X, Chang YT, Cao J, Zhang H, Sun M, Grippin AJ, Yang Z, Lu WJ, Lee LJ, Bahrani E, Zhang H, Bai L, Nguyen PK, Jiang W, Lan F, Kim BYS, Lee AS. Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy. Nature Biomed Eng, 2026. e-Pub 2026. PMID: 42277318.
- Ma Y, Dong S, Wu A, Jeong SD, Lee AS, Jiang W, Kim BYS. Engineering challenges and translational opportunities in emerging gene delivery platforms. Nature Biomed Eng 10(6):1060-1083, 2026. e-Pub 2026. PMID: 42092003.
- Chang YT, Richter FC, Jiang W. Protein homeostasis as a determinant of CD8(+) T cell fate. Nature Rev Immunol 26(7):487, 2026. e-Pub 2026. PMID: 42156576.
- Zhang, A, Ma, Y, Liu, Y, Dong, S, Torres, MN, Kim, YB, Liu, C, Sun, L, Yuan, Y, Jiang, W. Mannose Oligosaccharide-Conjugated In Situ Pore-Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles. Small Methods 10(3), 2026. e-Pub 2026. PMID: 40662273.
- Zhao L, O'Donnell KL, Dubey M, Wang Y, Martinez NR, Zhang Y, Steininger HM, Ma C, Mallajosyula V, Lee LLY, Lachmansingh RN, Stavitsky S, Takematsu E, Hoover MY, Chen H, Guo J, Wu A, Ma Y, Wang X, Nalin AP, Jeong SD, Lu WJ, Nguyen PK, Clancy CS, Tal MC, Xiao J, Longaker MT, Lee AS, Kim BYS, Ambrosi TH, Weissman IL, Davis MM, Hasenkrug KJ, Chien YH, Jiang W, Marzi A, Chan CKF. Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens. Nature Nanotechnol 21(3):419-429, 2026. e-Pub 2026. PMID: 41565781.
- Zhang, H, Sun, M, Chen, J, Wang, S, Liu, J, Yang, H, Liu, L, Hu, S, Yang, F, Teng, L, Chen, Z, Wang, X, Dong, S, Ma, Y, Edwards, J, Wang, X, Chang, YT, Kim, BY, Jiang, W, Cui, Y, Yang, Z. Immunological conversion of triple-negative breast cancer by engineered extracellular vesicle-mediated pyroptosis. Journal of Controlled Release 389, 2026. e-Pub 2026. PMID: 41344487.
- Ding, Q, Zhou, L, Xiong, T, Liu, J, Chen, L, Yoo, J, Xu, X, Jia, X, Chen, S, Chen, S, Wang, Y, Gong, P, Gu, M, Jiang, W, Kim, JS. Sunlight PDT leveraging NIR-II nanospray. National Science Review 13(2), 2026. e-Pub 2026. PMID: 41608042.
- Yeboa DN, Whitfield BT, Lin R, Ejezie CL, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J, McGovern SL, Harrison R, Majd NK, Puduvalli VK, Aaroe AE, Loghin M, O'Brien BJ, Patel AD, Patel CB, Wefel JS, Taslicay CA, Gule-Monroe M, Paulino AC, McAleer MF, Grosshans DR, Ghia AJ, Jiang W, Chung C, Maor M, Yang CH, Gubbiotti MA, Kamiya-Matsuoka C, Ballester LY, Weathers SP, Huse JT. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol 176(1):72, 2025. e-Pub 2025. PMID: 41191157.
- Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
- Ling AL, Gantchev J, Prabhu MC, Basu S, Ahn R, D'Souza A, Masud N, Ball A, Nikas O, Villa GR, Regan MS, Baquer G, Ayoub G, Whittaker CA, Abou-Mrad Z, Santos A, Couturier CP, Elharouni D, Vogelzang J, Yu KKH, Chen H, He Z, Jiang W, Lucas CH, Sax HE, Lang FF, Puduvalli VK, Tabar V, W Brennan C, Boire A, Holdhoff M, Bettegowda C, Cima M, Solomon IH, Yuan Y, Tak PP, Sharma P, White FM, Ligon KL, Agar NYR, Reardon DA, Oliveira G, Chiocca EA. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Sci Transl Med 17(819):eadv2881, 2025. e-Pub 2025. PMID: 41061048.
- Hou, M, Ma, Y, Deng, Y, Wu, Y, Zhu, Y, Liu, Y, Li, X, Yu, L, He, Z, Wang, Y, Dong, S, Xia, X, Yu, J, Yu, C, Kang, K, Lu, Y, Sun, L, Kim, BY, Yuan, Y, Zhang, Y, Jiang, W, Zhu, X. Therapeutic restoration of mitochondria–endoplasmic reticulum cross talk for osteoarthritis. Proceedings of the National Academy of Sciences of the United States of America 122(36), 2025. e-Pub 2025. PMID: 40892916.
- Grippin, A, Jiang, W. Mitochondrial proteins go public and novel interactions. Nature Reviews Immunology 25(9):636, 2025. e-Pub 2025. PMID: 40702235.
- Grippin, A, Lee, DY, Parkes, EE, Jiang, W, Kim, YB. Nanotechnology for immuno-oncology. Nature Cancer 6(8):1311-1325, 2025. e-Pub 2025. PMID: 40775548.
- Sun M, Zhang H, Ma Y, Wang S, Chen J, Cui Y, Zhang Y, Hu S, Zhou D, Zhang P, Liu Y, Kim BYS, Jiang W, Wang X, Yang Z. In Situ Programming of the Tumor Microenvironment to Alleviate Immunosuppression for Pancreatic Cancer Immunotherapy. Adv Sci (Weinh) 12(34):e04008, 2025. e-Pub 2025. PMID: 40548883.
- Yeboa DN, Li J, Lin R, Prabhu SS, Beckham TH, Woodhouse K, Swanson TA, Weinberg JS, Wang X, Chi X, Ejezie CL, Suki D, Wang C, Ene C, McCutcheon IE, McGovern S, McAleer MF, Tom M, Ghia A, Perni S, Jiang W, De B, Chung C, Kim BYS, O'Brien BJ, Huse JT, Wefel JS, Court L, Tawbi H, Janku F, Guha-Thakurta N, Debnam JM, Johnson J, Taslicay CA, Alvarez-Breckenridge C, Raza SM, Heimberger AB, DeMonte F, North R, Briere TM, de Groot JF, Sawaya R, Grosshans D, Lang FF, Rao G, Ferguson SD. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. JAMA Oncol, 2025. e-Pub 2025. PMID: 40531511.
- Zhang H, Xing J, Sun M, Cui Y, Li Y, Hu S, Wang X, Jiang H, Zhang Y, Jiang X, Yang F, Kim BYS, Jiang W, Yang Z, Teng L. Engineered exosomes for targeted microRNA delivery to reverse liver fibrosis. Biomaterials 324:123510, 2025. e-Pub 2025. PMID: 40561654.
- Wu A, Jiang W. Progenitor exhausted T cells contribute to the formation of immunological memory. Nature Rev Immunol 25(6):405, 2025. e-Pub 2025. PMID: 40329086.
- Wang Y, Song H, Teng Y, Huang G, Qian J, Wang H, Dong S, Ha J, Ma Y, Chang M, Jeong SD, Deng W, Schrank BR, Grippin A, Wu A, Edwards JL, Zhang Y, Lin Y, Poon W, Wilhelm S, Bi Y, Teng L, Wang Z, Kim BYS, Jiang W. A Generative Artificial Intelligence Copilot for Biomedical Nanoengineering. ACS Nano 19(20):19394-19407, 2025. e-Pub 2025. PMID: 40367350.
- Liu Z, Wang D, Li G, Yi M, Zhang Z, Zhong G, Xu L, Jiang R, Zheng Y, Huang L, Peng Y, Liang L, Li J, Liu Y, Lai J, Lv X, Xu Y, Liu Q, Wang Z, Liu Z, Yang Q, Nie L, Lei J, Huang X, Liu Z, Jiang W. Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial. Nature Commun 16(1):4608, 2025. e-Pub 2025. PMID: 40382318.
- Tang K, Tang Z, Niu M, Kuang Z, Xue W, Wang X, Liu X, Yu Y, Jeong S, Ma Y, Wu A, Kim BYS, Jiang W, Yang Z, Li C. Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions. Nature Commun 16(1):3410, 2025. e-Pub 2025. PMID: 40210849.
- Khorsandi S, Huntoon K, Wang Y, Woodward A, Antony A, Endsley C, Hafeez N, Edwards JL, McCuen N, Alluri PG, Kim BYS, Jiang W, Lux J. Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma. Adv Sci (Weinh) 12(22):e2416596, 2025. e-Pub 2025. PMID: 40135812.
- Schrank, BR, Wang, Y, Wu, A, Tran, N, Lee, DY, Edwards, J, Huntoon, K, Dong, S, Ha, JH, Ma, Y, Grippin, A, Jeong, S, Antony, A, Chang, M, Kang, M, Gallup, T, Koong, A, Li, J, Yun, K, Kim, BY, Jiang, W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 6(3):511-527, 2025. e-Pub 2025. PMID: 40000910.
- Schrank BR, Jiang W. An antibody-toxin conjugate enhances innate immune cell responses in tumors. Nature Cancer 6(3):415-416, 2025. e-Pub 2025. PMID: 40038505.
- Gao F, Liu X, Ma Z, Tang M, Tang Z, Wu J, Luo M, Tang Y, Wang X, Wang B, Kim BYS, Yang Z, Jiang W, Tang P, Li C. An Integrated Modular Vaccination System for Spatiotemporally Separated Perioperative Cancer Immunotherapy. Adv Mater 37(11):e2418322, 2025. e-Pub 2025. PMID: 39924759.
- You Y, Tian Y, Guo R, Shi J, Kwak KJ, Tong Y, Estania AP, Hsu WH, Liu Y, Hu S, Cao J, Yang L, Bai R, Huang P, Lee LJ, Jiang W, Kim BYS, Ma S, Liu X, Shen Z, Lan F, Phuong Nguyen PK, Lee AS. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. Eur Heart J 46(17):1662-1676, 2025. e-Pub 2025. PMID: 39831819.
- Wang Y, Schrank BR, Jiang W, Kim BYS. Learning what keeps nanomedicines in tumours. Nature Biomed Eng 8(11):1330-1331, 2024. e-Pub 2024. PMID: 39271934.
- Beckham TH, Rooney MK, McAleer MF, Ghia AJ, Tom MC, Perni S, McGovern S, Grosshans D, Chung C, Wang C, De B, Swanson T, Paulino A, Jiang W, Ferguson S, Patel CB, Li J, Yeboa DN. Hypofractionated radiotherapy for glioblastoma: A large institutional retrospective assessment of 2 approaches. Neurooncol Pract 11(3):266-274, 2024. e-Pub 2024. PMID: 38737610.
- Sun L, Niu H, Wu Y, Dong S, Li X, Kim BYS, Liu C, Ma Y, Jiang W, Yuan Y. Bio-integrated scaffold facilitates large bone regeneration dominated by endochondral ossification. Bioact Mater 35:208-227, 2024. e-Pub 2024. PMID: 38327823.
- Bian X, Yang L, Jiang D, Grippin AJ, Ma Y, Wu S, Wu L, Wang X, Tang Z, Tang K, Pan W, Dong S, Kim BYS, Jiang W, Yang Z, Li C. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles. Nature Commun 15(1):3987, 2024. e-Pub 2024. PMID: 38734698.
- Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong SD, Link TM, Gallup TD, Qie Y, Li X, Dong S, Schrank BR, Grippin AJ, Antony A, Ha J, Chang M, An Y, Wang L, Jiang D, Li J, Koong AC, Tainer JA, Jiang W, Kim BYS. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomed Eng 8(5):593-610, 2024. e-Pub 2024. PMID: 38641710.
- Chang M, Wang M, Liu B, Zhong W, Jana D, Wang Y, Dong S, Antony A, Li C, Liu Y, Zhao Z, Lin J, Jiang W, Zhao Y. A Cancer Nanovaccine Based on an FeAl-Layered Double Hydroxide Framework for Reactive Oxygen Species-Augmented Metalloimmunotherapy. ACS Nano 18(11):8143-8156, 2024. e-Pub 2024. PMID: 38436248.
- Li X, Huntoon K, Wang Y, Lee D, Dong S, Antony A, Walkey C, Kim BYS, Jiang W. Radiation Synergizes with IL-2/IL-15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity. Mol Cancer Ther 23(3):330-342, 2024. e-Pub 2024. PMID: 37956421.
- Wang Y, Deng W, Lee D, Yan L, Lu Y, Dong S, Huntoon K, Antony A, Li X, Ye R, Zhao Y, Zhao F, Schrank BR, Ha J, Kang M, Yang M, Gong P, Lorenzi PL, Tan L, Gallup TD, Tang SK, Yang Z, Li J, Sanford NN, Wang H, Kim BYS, Jiang W. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Nature Nanotechnol 19(2):255-263, 2024. e-Pub 2024. PMID: 37723279.
- Zhang J, Rima XY, Wang X, Nguyen LTH, Huntoon K, Ma Y, Palacio PL, Nguyen KT, Albert K, Duong-Thi MD, Walters N, Kwak KJ, Yoon MJ, Li H, Doon-Ralls J, Hisey CL, Lee D, Wang Y, Ha J, Scherler K, Fallen S, Lee I, Palmer AF, Jiang W, Magaña SM, Wang K, Kim BYS, Lee LJ, Reátegui E. Engineering a tunable micropattern-array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ. J Extracell Vesicles 12(11):e12369, 2023. e-Pub 2023. PMID: 37908159.
- Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, Chien MH, Zhang ZX, Hsu WH, Wang X, Zhang J, Li H, Sun L, Fallen S, Lee I, Chen XY, Chu YS, Zhang C, Cheng TS, Jiang W, Kim BYS, Reategui E, Lee R, Yuan Y, Liu HC, Wang K, Hsiao M, Huang CF, Shan YS, Lee AS, James Lee L. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nature Commun 14(1):6692, 2023. e-Pub 2023. PMID: 37872156.
- Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, Huntoon K, Jeong S, Ma Y, Li X, Deng W, Schrank BR, Grippin AJ, Ha J, Kang M, Chang M, Zhao Y, Sun R, Sun X, Yang J, Chen J, Tang SK, Lee LJ, Lee AS, Teng L, Wang S, Teng L, Kim BYS, Yang Z, Jiang W. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nature Commun 14(1):6610, 2023. e-Pub 2023. PMID: 37857647.
- You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu WH, Liu Y, Chiang CL, Schrank BR, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F, Kim BYS, Lee AS. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomed Eng 7(7):887-900, 2023. e-Pub 2023. PMID: 36635419.
- Huntoon K, Anderson SK, Ballman KV, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross OA, Cerhan JH, Whitton AC, Greenspoon JN, Parney IF, Ashman JB, Bahary JP, Hadjipanayis C, Urbanic JJ, Farace E, Khuntia D, Laack NN, Brown PD, Roberge D, Kim BYS. Association of Circulating Markers with Cognitive Decline After Radiation Therapy for Brain Metastasis. Neuro Oncol 25(6):1123-1131, 2023. e-Pub 2023. PMID: 36472389.
- Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BYS, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnol 17(12):1332-1341, 2022. e-Pub 2022. PMID: 36357792.
- Huang X, Liu Q, Zhong G, Peng Y, Liu Y, Liang L, Hong H, Feng W, Yang S, Zhang Y, Xian S, Li Z, Zhou Y, Zhang Z, Jiang W, Liang J, Liu ZG. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial. J Exp Clin Cancer Res 41(1):300, 2022. e-Pub 2022. PMID: 36224603.
- Li X, Khorsandi S, Wang Y, Santelli J, Huntoon K, Nguyen N, Yang M, Lee D, Lu Y, Gao R, Kim BYS, de Gracia Lux C, Mattrey RF, Jiang W, Lux J. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nature Nanotechnol 17(8):891-899, 2022. e-Pub 2022. PMID: 35637356.
- Li J, Xue C, Wang H, Dong S, Yang Z, Cao Y, Zhao B, Cheng B, Xie X, Mo X, Jiang W, Yuan H, Pan J. Hybrid Nanofibrous Composites with Anisotropic Mechanics and Architecture for Tendon/Ligament Repair and Regeneration. Small 18(27):e2201147, 2022. e-Pub 2022. PMID: 35686342.
- George J, Chen Y, Abdelfattah N, Yamamoto K, Gallup TD, Adamson SI, Rybinski B, Srivastava A, Kumar P, Lee MG, Baskin DS, Jiang W, Choi JM, Flavahan W, Chuang JH, Kim BY, Xu J, Jung SY, Yun K. Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors. Cancer Res Commun 2(6):402-416, 2022. e-Pub 2022. PMID: 36688010.
- George J, Chen Y, Abdelfattah N, Yamamoto K, Gallup TD, Adamson SI, Rybinski B, Srivastava A, Kumar P, Lee MG, Baskin DS, Jiang W, Choi JM, Flavahan W, Chuang JH, Kim BYS, Xu J, Jung SY, Yun K. Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors. Cancer Research Communications 2(6):402-416, 2022. e-Pub 2022.
- Hein DM, Deng W, Bleile M, Kazmi SA, Rhead B, De La Vega FM, Jones AL, Kainthla R, Jiang W, Cantarel B, Sanford NN. Racial and Ethnic Differences in Genomic Profiling of Early-Onset Colorectal Cancer. J Natl Cancer Inst 114(5):775-778, 2022. e-Pub 2022. PMID: 35134211.
- Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, Yang Y, Xu S, Yao H, Jiang W, Song E. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nature Commun 13(1):3011, 2022. e-Pub 2022. PMID: 35641481.
- Dong S, Bi Y, Sun X, Zhao Y, Sun R, Hao F, Sun Y, Wang Y, Li X, Deng W, Liu X, Ha J, Teng L, Gong P, Xie J, Kim BYS, Yang Z, Jiang W, Teng L. Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer. Small 18(16):e2107690, 2022. e-Pub 2022. PMID: 35277914.
- Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood SL, Powell SZ, Haviland DL, Parker Kerrigan BC, Lang FF, Prabhu SS, Huntoon KM, Jiang W, Kim BYS, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nature Commun 13(1):767, 2022. e-Pub 2022. PMID: 35140215.
- Sun Z, Deng G, Peng X, Xu X, Liu L, Peng J, Ma Y, Zhang P, Wen A, Wang Y, Yang Z, Gong P, Jiang W, Cai L. Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. Biomaterials 279:121228, 2021. e-Pub 2021. PMID: 34717198.
- Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clin Cancer Res 27(24):6800-6814, 2021. e-Pub 2021. PMID: 34593527.
- Liu Y, Yang Z, Wang L, Sun L, Kim BYS, Jiang W, Yuan Y, Liu C. Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossification-Mediated Bone Healing. Adv Sci (Weinh) 8(11):e2100143, 2021. e-Pub 2021. PMID: 34105266.
- Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X, Wu D, Huang Y. DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A 118(22), 2021. e-Pub 2021. PMID: 34035167.
- Ma Y, Yang Z, Huntoon K, Jiang W, Kim BYS. Advanced immunotherapy approaches for glioblastoma. Advanced Therapeutics 4(8), 2021. e-Pub 2021.
- Sun X, Yu K, Zhou Y, Dong S, Hu W, Sun Y, Li Y, Xie J, Lee RJ, Sun F, Ma Y, Wang S, Kim BYS, Wang Y, Yang Z, Jiang W, Li Y, Teng L. Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. ACS Appl Mater Interfaces 13(15):18152-18164, 2021. e-Pub 2021. PMID: 33764751.
- Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, da Veiga Leprevost F, Jaehnig EJ, Lei JT, Wen B, Schnaubelt M, Krug K, Song X, Cieslik M, Chang HY, Wyczalkowski MA, Li K, Colaprico A, Li QK, Clark DJ, Hu Y, Cao L, Pan J, Wang Y, Cho KC, Shi Z, Liao Y, Jiang W, Anurag M, Ji J, Yoo S, Zhou DC, Liang WW, Wendl M, Vats P, Carr SA, Mani DR, Zhang Z, Qian J, Chen XS, Pico AR, Wang P, Chinnaiyan AM, Ketchum KA, Kinsinger CR, Robles AI, An E, Hiltke T, Mesri M, Thiagarajan M, Weaver AM, Sikora AG, Lubinski J, Wierzbicka M, Wiznerowicz M, Satpathy S, Gillette MA, Miles G, Ellis MJ, Omenn GS, Rodriguez H, Boja ES, Dhanasekaran SM, Ding L, Nesvizhskii AI, El-Naggar AK, Chan DW, Zhang H, Zhang B, Analysis Consortium CPT. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39(3):361-379.e16, 2021. e-Pub 2021. PMID: 33417831.
- Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnol 16(1):6-15, 2021. e-Pub 2021. PMID: 33349682.
- Xie S, Shalaby-Rana E, Hester A, Honeycutt J, Fu CL, Boyett D, Jiang W, Hsieh MH. Macroscopic and microscopic imaging modalities for diagnosis and monitoring of urogenital schistosomiasis. Adv Parasitol 112:51-76, 2021. e-Pub 2021. PMID: 34024359.
- Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford NN, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Netw Open 3(12):e2028627, 2020. e-Pub 2020. PMID: 33295975.
- Westover KD, Mendel JT, Dan T, Kumar K, Gao A, Pulipparacharuv S, Iyengar P, Nedzi L, Hannan R, Anderson J, Choe KS, Jiang W, Abdulrahman R, Rahimi A, Folkert M, Laine A, Presley C, Cullum CM, Choy H, Ahn C, Timmerman R. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol 22(12):1831-1839, 2020. e-Pub 2020. PMID: 32347302.
- Wei W, Jiang H, Chen W, Zhou Y, Guo S, Zhong G, Zhou H, Wang S, Zhang H, Jiang W, Liu ZG. How should we implement radiotherapy for cancer patients in China during the endemic period of COVID-19?. Radiother Oncol 147:100-102, 2020. e-Pub 2020. PMID: 32259751.
- Wang L, Dong S, Liu Y, Ma Y, Zhang J, Yang Z, Jiang W, Yuan Y. Fabrication of Injectable, Porous Hyaluronic Acid Hydrogel Based on an In-Situ Bubble-Forming Hydrogel Entrapment Process. Polymers (Basel) 12(5), 2020. e-Pub 2020. PMID: 32429363.
- Wei W, Zhou J, Zhang Q, Liao DH, Liu QD, Zhong BL, Liang ZB, Zhang YC, Jiang R, Liu GY, Xu CY, Li Zhou H, Zhu SY, Yang N, Jiang W, Liu ZG. Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study. Cancer Med 9(8):2820-2832, 2020. e-Pub 2020. PMID: 32100444.
- Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin Cancer Res 26(7):1712-1724, 2020. e-Pub 2020. PMID: 31848190.
- von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun 11(1):1508, 2020. e-Pub 2020. PMID: 32198351.
- Zheng X, Zhang N, Qian L, Wang X, Fan P, Kuai J, Lin S, Liu C, Jiang W, Qin S, Chen H, Huang Y. CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. Int J Cancer 146(6):1730-1740, 2020. e-Pub 2020. PMID: 31840816.
- Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V, Chiang C, Deng W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BYS, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 4(1):69-83, 2020. e-Pub 2020. PMID: 31844155.
- Li N, Wang Y, Neri S, Zhen Y, Fong LWR, Qiao Y, Li X, Chen Z, Stephan C, Deng W, Ye R, Jiang W, Zhang S, Yu Y, Hung MC, Chen J, Lin SH. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun 10(1):4363, 2019. e-Pub 2019. PMID: 31554794.
- Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao L, Teo HY, Qiu J, Jiang W, Dong C, Wu D, Huang Y, Liu H. NCR- group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine 41:333-344, 2019. e-Pub 2019. PMID: 30827928.
- Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, Zhao H, Wang Y, Jiang W, Kim BYS. Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Adv Sci (Weinh) 6(5):1802070, 2019. e-Pub 2019. PMID: 30886813.
- An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS. Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 131:88-92, 2019. e-Pub 2019. PMID: 30773193.
- Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24(22):5744-5756, 2018. e-Pub 2018. PMID: 30068711.
- Zhang Z, Yang J, Ho A, Jiang W, Logan J, Wang X, Brown PD, McGovern SL, Guha-Thakurta N, Ferguson SD, Fave X, Zhang L, Mackin D, Court LE, Li J. A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images. Eur Radiol 28(6):2255-2263, 2018. e-Pub 2018. PMID: 29178031.
- Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
- Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res 24(2):341-350, 2018. e-Pub 2018. PMID: 29030353.
- Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys 99(4):812-816, 2017. e-Pub 2017. PMID: 29063850.
- Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8(1):1811, 2017. e-Pub 2017. PMID: 29180759.
- An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
- Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, Kim BYS, Yun K. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. Cancer Res 77(19):5360-5373, 2017. e-Pub 2017. PMID: 28807938.
- Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat Nanotechnol 12(8):763-769, 2017. e-Pub 2017. PMID: 28459470.
- Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys 98(5):1069-1077, 2017. e-Pub 2017. PMID: 28721890.
- Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi H, Li J. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol 133(3):595-602, 2017. e-Pub 2017. PMID: 28500560.
- Jiang W, Yuan H, Chan CK, von Roemeling CA, Yan Z, Weissman IL, Kim BYS. Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nat Rev Drug Discov 16(6):369-370, 2017. e-Pub 2017. PMID: 28303024.
- Jiang W, von Roemeling C, Qie Y, Chen Y, Liu X, Chen J, Kim BYS. Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering 1:0029, 2017. e-Pub 2017.
- Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BS. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. Int J Radiat Oncol Biol Phys 96(5):951-958, 2016. e-Pub 2016. PMID: 27742539.
- Jiang W, Liu J, Gullane PJ, Gentili F, Wharen RE, Kim BYS, DeMonte F. Non-contiguous meningeal metastases of olfactory neuroblastoma. J Neurooncol 126(1):201-203, 2016. e-Pub 2016. PMID: 26376653.
- Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Bell D. Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas. Head & Neck 38, (S1), E1459-E1466, 2016. e-Pub 2016. PMID: 26560893.
- Jiang W, Huang Y, An Y, Kim BY. Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano 9(9):8689-96, 2015. e-Pub 2015. PMID: 26212564.
- Liu J, Jiang W, Mao K, An Y, Su F, Kim BY, Liu Q, Jacobs LK. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat 150(2):439-45, 2015. e-Pub 2015. PMID: 25764167.
- Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, Pinto H, Lee-Enriquez N, Kong C, Le QT. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck 37(3):386-92, 2015. e-Pub 2015. PMID: 24431011.
- Kim BYS, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. J Neurooncol 118(2):405-412, 2014. e-Pub 2014. PMID: 24777756.
- Tang C, Komakula S, Chan C, Murphy JD, Jiang W, Kong C, Lee-Enriquez N, Jensen KC, Fischbein NJ, Le QT. Radiologic assessment of retropharyngeal node involvement in oropharyngeal carcinomas stratified by HPV status. Radiother Oncol 109(2):293-6, 2013. e-Pub 2013. PMID: 24103114.
- Chan CK, Lindau P, Jiang W, Chen JY, Zhang LF, Chen CC, Seita J, Sahoo D, Kim JB, Lee A, Park S, Nag D, Gong Y, Kulkarni S, Luppen CA, Theologis AA, Wan DC, DeBoer A, Seo EY, Vincent-Tompkins JD, Loh K, Walmsley GG, Kraft DL, Wu JC, Longaker MT, Weissman IL. Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. Proc Natl Acad Sci U S A 110(31):12643-8, 2013. e-Pub 2013. PMID: 23858471.
- Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popovic Z, Jain RK, Bawendi MG, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 108(6):2426-31, 2011. e-Pub 2011. PMID: 21245339.
- Liu W, Greytak AB, Lee J, Wong CR, Park J, Marshall LF, Jiang W, Curtin PN, Ting AY, Nocera DG, Fukumura D, Jain RK, Bawendi MG. Compact biocompatible quantum dots via RAFT-mediated synthesis of imidazole-based random copolymer ligand. J Am Chem Soc 132(2):472-83, 2010. e-Pub 2010. PMID: 20025223.
- Kim BY, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WC. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Lett 8(11):3887-92, 2008. e-Pub 2008. PMID: 18816147.
- Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3):145-50, 2008. e-Pub 2008. PMID: 18654486.
- Gryczynski I, Malicka J, Jiang W, Fischer H, Chan WC, Gryczynski Z, Grudzinski W, Lakowicz JR. Surface-plasmon-coupled emission of quantum dots. J Phys Chem B 109(3):1088-93, 2005. e-Pub 2005. PMID: 16851064.
Invited Articles
- Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufés C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol 14(7):629-635, 2019. e-Pub 2019. PMID: 31270452.
Review Articles
- Jeong SD, Schrank BR, Mancuso JJ, Kim BYS, Jiang W, Sharma P. Translational Challenges and Opportunities in mRNA Cancer Vaccines. Cancer Discov 16(9):1739-1749, 2026. e-Pub 2026. PMID: 42676099.
- Beckham TH, Dudzinski SO, Rooney MK, Faraj CA, Pasli M, Perni S, Tom M, Ghia A, Yeboa DN, McAleer MF, Swanson T, McGovern S, Wang C, Chung C, De B, Jiang W, Kim BYS, Ferguson SD, Tawbi HA, Glitza I, Le X, Kaya D, Dumbrava EE, Briere T, Mackin D, Li J. Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases. J Natl Compr Canc Netw 24(2):34-40, 2026. e-Pub 2026. PMID: 41671425.
- Ma, Y, Dong, S, Grippin, A, Teng, L, Lee, AS, Kim, BY, Jiang, W. Engineering therapeutical extracellular vesicles for clinical translation. Trends in Biotechnology 43(1):61-82, 2025. e-Pub 2025. PMID: 39227240.
- Wang Y, Xiao Z, Wang Z, Lee D, Ma Y, Wilhelm S, Wang H, Kim BY, Jiang W. Multi-omics approaches to decipher the interactions of nanoparticles and biological systems. Nature Rev Bioengineering 3:333–348, 2024. e-Pub 2024.
- Zhang H, Grippin A, Sun M, Ma Y, Kim BYS, Teng L, Jiang W, Yang Z. New avenues for cancer immunotherapy: Cell-mediated drug delivery systems. J Control Release 375:712-732, 2024. e-Pub 2024. PMID: 39326499.
- He Y, Wang Y, Wang L, Jiang W, Wilhelm S. Understanding nanoparticle-liver interactions in nanomedicine. Expert Opin Drug Deliv 21(6):829-843, 2024. e-Pub 2024. PMID: 38946471.
- Huntoon K, Lee D, Dong S, Antony A, Kim BYS, Jiang W. Targeting phagocytosis to enhance antitumor immunity. Trends Cancer 9(8):650-665, 2023. e-Pub 2023. PMID: 37150626.
- Lee, DY, Huntoon, K, Lux, J, Kim, BY, Jiang, W. Engineering nanomaterial physical characteristics for cancer immunotherapy. Nature Reviews Bioengineering 1(7):499-517, 2023. e-Pub 2023.
- Lee D, Huntoon K, Lux J, Kim BYS, Jiang W. Engineering nanomaterial physical characteristics for cancer immunotherapy. Nature Reviews Bioengineering 1:499-517, 2023. e-Pub 2023.
- Lee D, Huntoon K, Wang Y, Jiang W, Kim BYS. Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. Adv Mater 33(27):e2007576, 2021. e-Pub 2021. PMID: 34050699.
- Liu M, Wu K, Lin J, Xie Q, Liu Y, Huang Y, Zeng J, Yang Z, Wang Y, Dong S, Deng W, Yang M, Wu S, Jiang W, Li X. Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?. Front Pharmacol 12:695957, 2021. e-Pub 2021. PMID: 34305606.
- Gong P, Wang Y, Zhang P, Yang Z, Deng W, Sun Z, Yang M, Li X, Ma G, Deng G, Dong S, Cai L, Jiang W. Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy. Cancers (Basel) 13(1), 2020. e-Pub 2020. PMID: 33396603.
- Ziu M, Kim BYS, Jiang W, Ryken T, Olson JJ. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update. J Neurooncol 150(2):215-267, 2020. e-Pub 2020. PMID: 33215344.
- Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R. Intratumoral Immunotherapy for Early-stage Solid Tumors. Clin Cancer Res 26(13):3091-3099, 2020. e-Pub 2020. PMID: 32071116.
- Ma Y, Dong S, Li X, Kim BYS, Yang Z, Jiang W. Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy. Front Oncol 10:606906, 2020. e-Pub 2020. PMID: 33628730.
- Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19(10):568-586, 2019. e-Pub 2019. PMID: 31462760.
- Liu Z, Wang Y, Huang Y, Kim BYS, Shan H, Wu D, Jiang W. Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends Pharmacol Sci 40(9):613-623, 2019. e-Pub 2019. PMID: 31331639.
- Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res 25(6):1709-1717, 2019. e-Pub 2019. PMID: 30413527.
- Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS. Immunomodulating Nanomedicine for Cancer Therapy. Nano Lett 18(11):6655-6659, 2018. e-Pub 2018. PMID: 30185039.
- Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195-203, 2018. e-Pub 2018. PMID: 29332937.
- Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol 9:185, 2018. e-Pub 2018. PMID: 29556198.
- von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends Biotechnol 35(2):159-171, 2017. e-Pub 2017. PMID: 27492049.
- Jiang W, Chan CK, Weissman IL, Kim BYS, Hahn SM. Immune Priming of the Tumor Microenvironment by Radiation. Trends Cancer 2(11):638-645, 2016. e-Pub 2016. PMID: 28741502.
- D'Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol 6:212, 2016. e-Pub 2016. PMID: 27774435.
- Jiang W, Kim BY, Rutka JT, Chan WC. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv 4(6):621-33, 2007. e-Pub 2007. PMID: 17970665.
- Jiang W, Papa E, Fischer H, Mardyani S, Chan WC. Semiconductor quantum dots as contrast agents for whole animal imaging. Trends Biotechnol 22(12):607-9, 2004. e-Pub 2004. PMID: 15542145.
Editorials
- Ha J, Grippin AJ, Kim BYS, Jiang W. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody. Cancer Res 84(10):1546-1547, 2024. PMID: 38745496.
- Huntoon K, Jiang W, Kim BY. Waking immune-resistant tumors with neddylation. J Clin Invest 133(4), 2023. PMID: 36787255.
- Tang C, Jiang W, Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword. JAMA Oncol 4(8):1116-1117, 2018. PMID: 29327039.
- Jiang W. A tale of two disciplines. Nat Nanotechnol 11(8):732, 2016. PMID: 27485586.
Abstracts
- Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Bell D. Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas. Head & Neck 38, (S1), E1459-E1466, 2016. e-Pub 2016.
Book Chapters
- Yoon JW, Jiang W, Huang YH, Rutka JT, Kim BYS. Perspectives of nanotechnology in the management of gliomas. In: Chernov MF, Muragaki Y, Kesari S, McCutcheon IE. Progress in Neurological Surgery. 1st ed. Karger, 2015.
- Jiang W, Singhal A, Fischer H, Mardyani S, Chan WCW. Engineering biocompatible quantum dots for real-time, ultrasensitive biological imaging and detection. In: Therapeutic Micro/Nanotechnology, Bhatia S, and Desai T, eds. Kluwer Publishing, 2006.
- Mardyani S, Jiang W, Lai J, Zhang J, Chan WCW. Bioinspired approaches to build nanoscale devices. In: Biological Nanostructures and Applications of Nanostructures in Biology, Stoscio M, and Dutta M, eds. Kluwer Publishing, 2004.
Patents
- Kim BYS, Wharen Jr RE, Yuan H, Jiang W. Methods and materials for treating cancer. Patent Number: US Patent: 288329.
- Jiang W, Mardyani S, Fischer H, Chan WCW. Stable, water-soluble quantum dot, method of preparation and conjugates thereof. Patent Number: US patent: 7151047, CA patent: 2505655.
Patient Reviews
CV information above last modified September 09, 2026